Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study ...

Discover a study that concludes that the DermSat-7 is a valid and reliable instrument for measuring treatment satisfaction in ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...